Advanced Adult Hepatocellular Carcinoma Clinical Trial
Official title:
A Pilot Study of Stereotactic Liver Irradiation for Hepatocellular Carcinoma
This pilot clinical trial studies stereotactic body radiation therapy in treating patients with liver cancer that cannot be removed by surgery. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
PRIMARY OBJECTIVES: I. To evaluate feasibility and safety of stereotactic body radiation therapy (SBRT) of the liver for treatment of hepatocellular carcinoma (HCC). SECONDARY OBJECTIVES: I. To evaluate radiographic local response, local control and time to local progression (TTLP) of treated lesions in HCC patients after liver SBRT. II. To evaluate overall survival (OS) and cancer specific survival (CSS) in HCC patients treated with liver SBRT. III. To evaluate explanted irradiated liver tissue (for patients who proceed to liver transplantation) to determine extent of residual tumor and extent of radiation effects within and around the irradiated field. OUTLINE: Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity. After completion of study treatment, patients are followed up at 1, 3, 6, 9, and 12 months and then every 6 months for up to 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01010126 -
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
|
Phase 2 | |
| Completed |
NCT01900002 -
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT02234986 -
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
|
Phase 2 | |
| Completed |
NCT02578602 -
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
|
Phase 1 | |
| Completed |
NCT00608361 -
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
|
Phase 1 | |
| Completed |
NCT02072486 -
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
N/A | |
| Completed |
NCT01839604 -
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
|
Phase 1 | |
| Completed |
NCT04576572 -
Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma
|
||
| Recruiting |
NCT04022746 -
An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer
|
N/A | |
| Completed |
NCT01666756 -
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
|
Phase 1 | |
| Completed |
NCT02409524 -
An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects
|
Phase 2 | |
| Recruiting |
NCT02418988 -
Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Terminated |
NCT01405573 -
Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
|
Phase 3 | |
| Completed |
NCT01835223 -
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
| Completed |
NCT01777594 -
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT01829035 -
A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC
|
Phase 3 | |
| Active, not recruiting |
NCT02042443 -
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT01015833 -
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03211416 -
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01488487 -
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
|
Phase 2 |